FDA advisers vote against sleep peptide as they debate safety and health claims

During a two-day meeting, the FDA's advisory committee debated whether to approve seven peptides, including a popular sleep peptide, for compounding. The panel ultimately voted against the sleep peptide due to concerns over its safety and efficacy. This decision highlights the FDA’s stringent approach to new wellness products, emphasizing the need for rigorous testing before they can be marketed. The debate underscores the growing tension between emerging health trends and regulatory oversight.